Wei Liangzhe, Chen Siqi, Deng Xinpeng, Liu Yuchun, Wang Haifeng, Gao Xiang, Huang Yi
Department of Neurosurgery, Ningbo Hospital, Zhejiang University School of Medicine, Ningbo, 315010, China.
Ningbo Key Laboratory of Neurological Diseases and Brain Function, Department of Neurosurgery, The First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang, 315010, China.
Biomark Res. 2024 Jun 20;12(1):63. doi: 10.1186/s40364-024-00608-7.
Ischemic stroke (IS), a devastating cerebrovascular accident, presents with high mortality and morbidity. Following IS onset, a cascade of pathological changes, including excitotoxicity, inflammatory damage, and blood-brain barrier disruption, significantly impacts prognosis. However, current clinical practices struggle with early diagnosis and identifying these alterations. Metabolomics, a powerful tool in systems biology, offers a promising avenue for uncovering early diagnostic biomarkers for IS. By analyzing dynamic metabolic profiles, metabolomics can not only aid in identifying early IS biomarkers but also evaluate Traditional Chinese Medicine (TCM) efficacy and explore its mechanisms of action in IS treatment. Animal studies demonstrate that TCM interventions modulate specific metabolite levels, potentially reflecting their therapeutic effects. Identifying relevant metabolites in cerebral ischemia patients holds immense potential for early diagnosis and improved outcomes. This review focuses on recent metabolomic discoveries of potential early diagnostic biomarkers for IS. We explore variations in metabolites observed across different ages, genders, disease severity, and stages. Additionally, the review examines how specific TCM extracts influence IS development through metabolic changes, potentially revealing their mechanisms of action. Finally, we emphasize the importance of integrating metabolomics with other omics approaches for a comprehensive understanding of IS pathophysiology and TCM efficacy, paving the way for precision medicine in IS management.
缺血性中风（IS）是一种毁灭性的脑血管意外，具有高死亡率和高发病率。IS发作后，一系列病理变化，包括兴奋性毒性、炎症损伤和血脑屏障破坏，会显著影响预后。然而，目前的临床实践在早期诊断和识别这些变化方面存在困难。代谢组学作为系统生物学中的一种强大工具，为发现IS的早期诊断生物标志物提供了一条有前景的途径。通过分析动态代谢谱，代谢组学不仅有助于识别早期IS生物标志物，还能评估中药疗效并探索其在IS治疗中的作用机制。动物研究表明，中药干预可调节特定代谢物水平，这可能反映了它们的治疗效果。识别脑缺血患者中的相关代谢物对于早期诊断和改善预后具有巨大潜力。本综述重点关注近期代谢组学在IS潜在早期诊断生物标志物方面的发现。我们探讨了在不同年龄、性别、疾病严重程度和阶段观察到的代谢物变化。此外，该综述还研究了特定中药提取物如何通过代谢变化影响IS的发展，这可能揭示它们的作用机制。最后，我们强调将代谢组学与其他组学方法相结合对于全面理解IS病理生理学和中药疗效的重要性，为IS管理中的精准医学铺平道路。
